Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915523 · ClinicalTrials.gov registry record · Phase 1
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02915523 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 140 participants.
The verdict
NCT02915523, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose in terms of progression free survival compared to avelumab plus placebo in participants with refractory or recurrent epithelial ovarian cancer.
Interventions
- DRUG Placebo
- DRUG entinostat
- DRUG avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02915523
The ClinicalTrials.gov registry entry for NCT02915523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02915523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02915523 about?
NCT02915523 is a clinical study titled "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer". The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose i...
What is the current status of trial NCT02915523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2016-12-19. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT02915523?
The interventions under investigation include: Placebo (DRUG), entinostat (DRUG), avelumab (DRUG).
Who is sponsoring clinical trial NCT02915523?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.